Drug Trial Radar · NCT07282587
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Jan 2, 2026
Primary completion
Dec 15, 2028
Study completion Dec 15, 2028
Sponsor
- Lead sponsor
- Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
- Sponsor type
- Industry
- First posted
- Dec 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a two-stage Phase 2 trial evaluating the efficacy and safety of ONC206 in participants with Pheochromocytoma and Paraganglioma (PCPG).
Conditions
- Advanced Pheochromocytoma and Paraganglioma
- PCPG
Interventions
ONC206Drug
150 mg BID TIW
ONC206: Dose 1Drug
ONC206: Dose 2Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: Up to 36 months.
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
UCLA
Los Angeles, California · Recruiting
Stanford
Palo Alto, California · Recruiting
U of Colorado
Aurora, Colorado · Recruiting
U of Michigan
Ann Arbor, Michigan · Recruiting
Mayo-Rochester
Rochester, Minnesota · Recruiting
Washington University
St Louis, Missouri · Recruiting
Columbia University Irving Medical Center
New York, New York · Recruiting
PENN
Philadelphia, Pennsylvania · Recruiting
UTAH
Salt Lake City, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.